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Ataxia-telangiectasia (AT) is a neurodegenerative disorder characterized by ataxia, telangiectasia, and immuno-
deficiency. An increased risk ofmalignancies and respiratory diseases dramatically reduce life expectancy. To bet-
ter counsel families, develop individual follow-up programs, and select patients for therapeutic trials, more
knowledge is needed on factors influencing survival. This retrospective cohort study of 61 AT patients shows
that classical AT patients had a shorter survival than variant patients (HR 5.9, 95%CI 2.0–17.7), especially once
a malignancy was diagnosed (HR 2.5, 95%CI 1.1–5.5, compared to classical AT patients without malignancy). Pa-
tients with the hyper IgM phenotype with hypogammaglobulinemia (AT-HIGM) and patients with an IgG2 defi-
ciency showed decreased survival compared to patients with normal IgG (HR 9.2, 95%CI 3.2–26.5) and patients
with normal IgG2 levels (HR 7.8, 95%CI 1.7–36.2), respectively. If high risk treatment trials will become available
for AT, those patients with factors indicating the poorest prognosis might be considered for inclusion first.
©2018TheAuthors. Publishedby Elsevier Inc. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Ataxia-telangiectasia (AT; OMIM 208900) is an autosomal recessive
neurodegenerative disease caused by mutations in the ataxia telangiec-
tasia mutated (ATM) gene [1]. The ATM gene codes for ATM kinase,
which plays a role in cell cycle control and DNA repair [2]. Over 400
ATMmutationshave beendescribed so far [3]. AT is characterized by cer-
ebellar ataxia, oculocutaneous telangiectasia, increased radiosensitivity,
growth retardation, predisposition to malignancies and diabetes
mellitus type II, and a primary cellular and humoral immunodeficiency
causing recurrent sinopulmonary infections [4]. The immunodeficiency
is caused by impaired double-strand break repair processes, such as
V(D)J recombination [5] and class-switch recombination [6,7], and
features a reduced number of circulating T-cells (in particular
CD3 + CD4 + CD45RA+ naïve T-cells) and B-cells, frequently causing
decreased or absent serum IgA and IgG2 [8,9]. An estimated 10% of AT
patients have decreased IgA and IgG levels with normal to increased
IgM levels [10], designated as ‘hyper IgM phenotype with
hypogammaglobulinemia’ (AT-HIGM). AT is incurable and patients
have a reduced life expectancy due to cancer, pulmonary disease, and
infections [11].
The clinical spectrum of AT is variable [12] with residual kinase ac-
tivity and the related type of ATM mutation contributing to the life
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Table 1
Features of 61 AT patients from the Netherlands and Iceland.
No Sex Ethnicityc Age
or age
at
death
ATM mutations Immunoglobulin
levels
Cancer type Cause of death Immunoglobulin
therapy
Antibiotic
prophylaxis
Allele 1 Allele 2 IgG IgG2 IgA IgM
Group 1a
Classical AT patients, ATM protein
absent, AT-HIGM phenotype
1 M NL 13b Exon 19–61
c.2467 + 1551 del 97 kb
Exon 19–61
c.2467 + 1551 del
97 kb
D D D N Lymphoma Malignancy Yes Yes
2a F AF 9b Exon 37 c.5188C N T Exon 37 c.5188C N T D D D N – Respiratory failure Yes x
2b F AF 12b Exon 37 c.5188C N T Exon 37 c.5188C N T D D D N – Respiratory failure Yes Yes
2c M AF 10b Exon 37 c.5188C N T Exon 37 c.5188C N T D D D N Hepatocellular
carcinoma
Malignancy Yes x
3 F MO 14b Exon 21 c.2921 + 5G N A Exon 21
c.2921 + 5G N A
D D D N – Respiratory failure Yes Yes
4a F BE 9b Exon 12
c.1563_1564delAG
Exon 39 c.5515C N T D D D N Lymphoma Malignancy Yes Yes
5 F IC 12b Exon 19 c.2554C N T Exon 19 c.2554C N T D D D N – Respiratory failure Yes Yes
Group 1b
Classical AT patients, ATM protein
absent
6 M NL 20 Exon 9 c.790_790delT Exon 12
c.1563_1564delAG
N D D N – – Yes Yes
7 F NL 22b Exon 10
c.1027_1030delGAAA
Exon 13
c.1660_1660delA
N D D N B-cell non-Hodgkin
lymphoma
Urinary tract bleedingd Yes No
8 F TR 9b Exon 12
c.1514_1515delTT
Exon 12
c.1514_1515delTT
↑ x N ↑ Hodgkin lymphoma Malignancy Yes Yes
9a F NL 21b Exon 12
c.1563_1564delAG
Exon 39 c.5515C N T N N N N – Not noted No No
9b F NL 10b Exon 12
c.1563_1564delAG
Exon 39 c.5515C N T N D N N B-cell lymphoma Malignancy No No
10 M TR 12 Exon 43 c.6082C N T Exon 43 c.6082C N T N D D N – – No Yes
11e M NL 40b Exon 12 c.1563_
1564delGA
Exon 23 c.3078 G N T D-N D D N-↑ B-cell non-Hodgkin
lymphoma
Malignancy Tempo-rarily No
12 M AN 22 Exon 27 c.3741-1G N C Exon 37 c.5197G N C N D D N – – Tempo-rarily No
13a M NL 54b Exon 6 c.331 + 5G N A Exon 29 c.4040delT N N N ↑ Prostate cancer Malignancy No No
14a M IC 15 Exon 6 c.309C N G Exon 12 c.1369C N T N D D N – – No No
Group 2
Classical AT patients, ATM protein
present, no kinase activity
15a F IR 9b Exon 61 c.8633T N G Unidentified x x x x Hodgkin lymphoma Malignancy No Yes
15b M IR 26b Exon 61 c.8633T N G Unidentified N-D D N N Hodgkin lymphoma Malignancy Yes Yes
16 F NL 13 Exon 48 c.6629delA Exon 60
c.8578_8580delTCT
N N D N – – Yes Yes
17a M NL 15 Exon 55
c.7875_7876delTGinsGC
Exon 55
c.7875_7876delTGinsGC
N D N N – – No Yes
17be F NL 4b Exon 55
c.7875_7876delTGinsGC
Exon 55
c.7875_7876delTGinsGC
D-N D D-N N Acute lymphoblastic
leukemia
Pulmonary
hypertensiond
Tempo-rarily Yes
18a F NL 22b Exon 55
c.7875_7876delTGinsGC
Exon 55
c.7875_7876delTGinsGC
N-D D N N – Respiratory failure Yes Yes
18b M NL 10b Exon 55
c.7875_7876delTGinsGC
Exon 55
c.7875_7876delTGinsGC
N D D N Lymphoma Respiratory
failure/malignancy
No No
19 F NL 27b Exon 55
c.7875_7876delTGinsGC
Exon 60
c.8578_8580delTCT
N-↑ N D N Breast cancer Respiratory
failure/malignancy
x x
20a M NL 26b Exon 41 c.5762–2 A N T Unidentified N D N N – Respiratory failure No Yes
20b M NL 14b Exon 41 c.5762–2 A N T Unidentified N x D N – Respiratory failure No Yes
21 M NL 21 Exon 6 c.331 + 5G N A Exon 55
c.7875_7876delTGinsGC
N N D N – – No No
22 F TR 22 Exon 26 c.3576 G N A Exon 26 c.3576 G N A N N N N – – No Yes
23a F TR 24b Exon 26 c.3576G N A Exon 26 c.3576G N A x x x x Dermatofibro-sarcoma
protuberans
Resuscitation needed
for unknown cause
No No
23b M TR 35 Exon 26 c.3576G N A Exon 26 c.3576G N A N D ↑ N Dermatofibro-sarcoma
protuberans
– No No
24aa M NL 32 Exon 29 c.4109 + 5G N A Exon 55
c.7875_7876delTGinsGC
N D D N – – No No
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24ba F NL 28 Exon 29 c.4109 + 5G N A Exon 55
c.7875_7876delTGinsGC
↑ N ↑ ↑ – – No No
25a,f F NL 9 Exon 14. c1898 + 2T N G Exon 32 c.4477C N G D D N N – – Yes No
26 a M TR 7 Exon 48 c.6679C N T Exon 48 c.6679C N T N N D N – – No No
27a M IC 7 Exon 12 c.1369 Exon 65 c.9139C N T N x N N – – No x
Group 3
Classical AT patients, no data on ATM
protein and kinase activity
28 M TN 17b Exon 14 c.1810C N T Exon 47 c.6482 GN C ↑ x N ↑ Non-Hodgkin
lymphoma
Not noted x x
29 F NL 25 Exon 17 c.2376 + 1G N A Exon 55
c.7875_7876delTGinsGC
x x x x – – x x
30 M KR/GE 9b Exon 12
c.1563_1564delAG
Exon 53 c.7542T N G N D D ↑ T-cell lymphoma Malignancy No No
31 M TR 15b Exon 58 c.8264dupA Exon 58 c.8264dupA N x N N T-cell acute
lymphoblastic
leukemia
Asystole after
extubationd
No No
32 F NL 15b Exon 9
c.738_739delCTinsA
Exon 55
c.7875_7876delTGinsGC
N x D N B-cell lymphoma Respiratory
failure/malignancy
No Yes
33 M NL 18 Exon 7 c.484C N T Exon 14
c.1898 + 2T N G
N D N N Lymphoma – Yes Yes
34a F NL 10b Exon 65 c.9019 G N T Unidentified N D D N – Respiratory failure Yes Yes
35a F SR 49 Exon 20
c.2839-579_2839-576del4
Exon 31 c.4396C N T ↑ N ↑ N – – No x
35b F SR 50 Exon 20
c.2839-579_2839-576del4
Exon 31 c.4396C N T ↑ x ↑ ↑ – – No x
36 M NL 17b Exon 20 c.2662 G N T Exon 48 c.6679C N T N D N N B-cell non-Hodgkin
lymphoma
Malignancy x No
37a F SR 9 Exon 19 c.2620G N T Exon 31
c.4344_4345delAT
N D D ↑ – – No Yes
38a M NL 4 Exon 12
c.1564_1565delGA
Exon 55
c.7875_7876delTGinsGC
N N D N – – No x
Group 4
Variant AT patients, ATM protein
present, residual kinase activity
39 F NL 54 Exon 7 c.496 + 5G N A Exon 55
c.7875_7876delTGinsGC
x x x x – – No No
40 F NL 47b Exon 57 c.8147T N C Exon 12
c.1391_1395delTGTGT
N x N x Breast cancer, chronic
myeloid leukemia
Malignancy No No
41 F NL 43 Exon 57 c.8147T N C Unidentified N N N N Breast cancer – No No
42 F NL 56 Exon 9 c.717_720delCCTC Exon 57 c.8147T N C x x x x – – No No
43 F NL 40 Exon 42 c.5932 G N T Exon 57 c.8147 T N C N N N N – – No No
44a F NL 39 Exon 21 c. 2909T N G Exon 49 c.6908dupA N N N N – – No No
44b M NL 23b Exon 21 c. 2909T N G Exon 49 c.6908dupA x x x x Ectopic pituitary tumor Malignancy No No
45a M NL 39 Exon 6 c.331 + 5G N A Exon 6 c.331 + 5G N A N N N N – – No No
45b F NL 42 Exon 6 c.331 + 5G N A Exon 6 c.331 + 5G N A N D N N – – No No
46 F NL 56 Exon 22 c.2922-1G N A Exon 57 c.8147T N C N N N N – – No No
47a M NL 48b Exon 23 c.3136C N T Exon 53 c.7622T N G N N N N Pancreatic cancer Malignancy No No
47b M NL 51 Exon 23 c.3136C N T Exon 53 c.7622T N G N N N N – – No No
47c M NL 51b Exon 23 c.3136C N T Exon 53 c.7622 T N G x x x x Acute lymphoblastic
leukemia
Malignancy No No
a-b-c patients are siblings.
a Patient was not described before by Verhagen et al. (n= 11).
b Patient is deceased.
c NL=Dutch; AF=Afghan; MO=Moroccan; BE= Belgian; IC= Icelandic; TR= Turkish; AN=Antillean; IR= Iranian; TN= Tunisian; KO=Korean; GE=German; SR= Surinamese; D= deficient; N= normal; ↓=decreased (compared to
age-related reference values [17,18]); x = not measured or unknown.
d Cause of death was a complication of malignancy treatment.
e Patient 17b was excluded from our IgA immunoglobulin analysis since IgA levels were variable during life. Patients 11, 15b, and 18a were excluded from the AT-HIGM group since IgG levels were variable during life.
f Patient 25 was excluded from group 1a (AT-HIGM) since she had normal IgA levels and her IgG level increased to normal after only two gifts of immunoglobulin replacement therapy.
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expectancy [11,13]. Variant AT patients have a milder clinical pheno-
type and a longer lifespan compared to classical AT patients [11–13];
their longer life expectancymay be attributed to less severe immunode-
ficiency [8,9] and delayed onset of cancer [11].
Much is known about the pathogenesis of AT but knowledge of fac-
tors predicting survival is lacking. To further individualize follow-up
programs for AT patients, and eventually select eligible patients for fu-
ture therapeutic trials, better knowledge on factors that contribute to
survival is needed.
The aim of this study was to identify such factors in both classical
and variant AT.
2. Material and methods
2.1. Ascertainment of study cohort
Data were retrospectively collected from Dutch and Icelandic co-
horts of AT patients. For patients previously described by Verhagen
et al. [13], the follow-up period was extended by six years. The clinical
diagnosis of AT was confirmed by the identification of pathogenic ATM
mutations in all subjects. The ATMmutation analysis and the measure-
ments of ATMprotein and ATMkinase activity in patients with available
lymphoblast cell lines were performed using previously described
methods [14,15]. Data on age, gender, nationality, age and cause of
death, immunoglobulin levels of IgA, IgG, IgG2, IgM, and lymphocyte
subsets (all pre-treatment, in case of immunoglobulin replacement
therapy), and presence of cancer were collected from the cohort data-
base or the medical records of the patient's primary hospital. Immuno-
globulin plasma levels and lymphocyte subsets were assessed using
methods previously described [16], and compared to age-related refer-
ence values [17,18]. The follow-up period was defined as starting at
birth and continuing until death or August 31, 2014, whichever came
first. Patients lost to follow-up were excluded from the study. This
study was approved by the Regional Committee on Research involving
Human Subjects Arnhem-Nijmegen.
2.2. Patient definitions
The patients were classified into four groups, based on the presence
of ATM protein and ATM kinase activity. The classical AT patients com-
prised patientswithout detectable ATMprotein (group 1), patientswith
ATM protein but without ATM kinase activity (group 2), and patients
with missing data on ATM protein and ATM kinase activity, but with
clinical phenotypes similar to those in groups 1 and 2 (Supplement
1) (group 3). Group 4 consisted of variant AT patients with residual ki-
nase activity. Patients with decreased IgG and IgA levels but with
Fig. 1. Flow charts of the cohort.
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normal or elevated IgM levels at the time of diagnosis were classified as
AT-HIGM (group 1a), and those with normal total IgG levels as group
1b.
2.3. Literature search
To supplement the data from our cohort, we searched all available
literature for reports on patients with AT-HIGM. We searched all avail-
able literature until January 2016 through the electronic databases
PubMed, EMBASE, the Cochrane Library, andWeb of Science. For all pa-
tients that were alive at time of publication, the first authors of the pa-
pers were contacted for additional information on survival.
2.4. Statistical analysis
Using IBM SPSS statistics 22.0 for Windows (IBM SPSS Inc., Chicago,
IL, USA), we performed descriptive statistics and logistic regression
analyses to calculate odds ratios (OR) with 95% confidence intervals
(95%CI) for associations between immunoglobulin deficiencies and AT
phenotypes. Differences in survival between groups were assessed
using Cox proportional hazard models to calculate hazard ratios (HR)
with 95%CIs, which are more informative than p-values. The OR and
HR represents the strength of the association, while the 95%CI shows
the imprecision in the estimate. Confidence intervals that do not or
only just include the null value (OR/HR=1) are indicative of statistical-
ly significant and/or noticeable results. To avoid interpretation prob-
lems because of low numbers in multivariable analyses, the HRs were
only adjusted for gender. In sensitivity analyses, patients with
b10 years of follow-up (n = 11, al classical AT) were excluded.
GraphPad Prism v5.03 was used to display Kaplan Meier survival prob-
ability curves from birth through August 2014, at which point patients
were censored if the event (e.g. death or malignancy) had not yet
occurred.
3. Results
3.1. Cohort description
The total cohort consisted of 63 patients. Two patients that were lost
to follow-upwere excluded from the analysis, leading to inclusion of 61
AT patients (29 male and 32 female patients), divided into 48 patients
with classical AT (17 in group 1, 19 in group 2, and 12 in group 3) and
13 patients with variant AT (Table 1 and Figure 1a). In total, 50 of
these patients were previously described by our research group [13]
in a genotype-phenotype correlation study, while 27 patients were
also described in other reports [8,19–23].
The ages of the patients ranged from 4 to 56 years. At the end of
follow-up, 32 patients were deceased and 29 were alive. In the latter
group, 16 patients, all with classical AT, were still under 30 years of
age (Figure 1b). Among 48 classical AT patients, only six patients
(12.5%) survived beyond 30 years of age: two in group 1 and four in
group 2. The two patients from group 1 died at ages 40 and 54 fromma-
lignancies, whereas the other four patientswere 35, 32, 49, and 50 years
old and still alive at the endof follow-up. Among the variant AT patients,
all but one survived beyond 30 years of age. Fifty different mutations in
33 exons were found in the cohort, while 19 patients had homozygous
ATMmutations (Table 1).
IgG2 subclass plasma levels were measured in 46 out of the 61 pa-
tients (38 with classical AT and 8 with variant AT), of whom 29 had
an IgG2 deficiency. Only one IgG2 deficiency was observed in a variant
AT patient. IgA levels were measured in 53 patients, of whom 25 had
an IgA deficiency. None of the variant AT patients had IgA deficiency.
IgG and IgM levels were normal in the majority of patients, but 7 classi-
cal AT patients without expression of ATMprotein had AT-HIGM (group
1a). Among thepatients in this groupwith normal IgG levels (group1b),
78%were IgG2 deficient compared to 60% in group 2 (OR 2.3, 95%CI 0.4–
15.3), with IgA deficiency in 60% of patients in group 1b versus 41% in
group 2 (OR 3.6, 95%CI 0.8–17.0). The lymphocyte subsets of patients
from group 1a (AT-HIGM group) are shown in Supplement 2.
Fig. 2. Survival of patients with classical (group 1,2,3) and variant (group 4) AT.
49N.J.H. van Os et al. / Clinical Immunology 178 (2017) 45–55
3.2. Survival analyses
As shown in Fig. 2, patients with classical AT generally died at a
much younger age than variant AT patients. The corresponding hazard
ratio for classical AT compared to variant AT was 5.9 (95% CI 2.0–
17.7). Only very slight differences in HR were observed when gender
was included as co-variable and after exclusion of AT-HIGM patients
or patients with b10 years of follow-up (Supplement 3).
Classical AT patients without detectable ATM protein (group
1) seemed to have a slightly lower chance of survival compared to pa-
tients with ATM protein without kinase activity (group 2) (HR 1.8,
95%CI 0.7–4.4; HR adjusted for gender (HRgender 2.2, 95%CI 0.9–5.7))
(Supplements 3 and 4).When group 1awas excluded from the analysis,
patients without detectable ATM protein (group 1b) and patients with
ATM protein without kinase activity (group 2) did not differ in survival
(HR 0.9, 95% CI 0.3–3.0).
3.3. Malignancy
Among the classical AT patients, 21 (44%) had a malignancy com-
pared to 5 patients (38%) in the variant group, with a median age at
first diagnosis of 15 (range 4–52) and 42 (range 23–51), respectively.
Of the 21 classical AT patients with a malignancy, 16 had a hematolog-
ical malignancy, mostly lymphomas (n = 14), and 19 patients died:
17 (81%) due to their malignancy and two from unknown causes
(Table 1). Of these 19 patients, 17 died within one year after diagnosis.
In the variant group, all five cancers developed in adulthood and four
patients died of their malignancy: two of leukemia at ages 47 and 51
and two of solid tumors at ages 23 and 48 (Fig. 3 and Supplement 5).
AT patients with a malignancy showed reduced survival compared
to patients without a malignancy (HR 3.7, 95%CI 1.7–8.1), especially
when patientswith the AT-HIGMphenotype,whohad anoverall poorer
survival, were excluded (HR 5.9, 95%CI 2.2–15.7) (Supplement 3). The
corresponding HR when having a malignancy was 2.5 (95%CI 1.1–5.5)
for the classical group, but could not be calculated for the variant
group due to low numbers. Adjustment for gender and exclusion of pa-
tients with b10 years of follow-up slightly increased or decreased the
HRs, respectively. Classical AT patients without a malignancy and vari-
ant AT patientswith amalignancyhad a similar overall chance of surviv-
al (HR 1.1, 95%CI 0.3–3.8).
3.4. Immunology
3.4.1. IgG2 deficiency
AT patients with an IgG2 deficiency had greatly reduced survival
compared to patients with normal IgG2 levels (HR 10.2, 95%CI 2.3–
45.0), even when the analyses were restricted to classical AT patients
(HR 5.3, 95%CI 1.2–23.5). With adjustment for gender, both of these
HRs increased to 13, as more female patients with IgG2 deficiencies
died and at a younger age compared to male patients (Supplement 3).
When the AT-HIGM phenotype was excluded in order to prevent bias,
Fig. 3. Survival of AT patients with and without malignancy (in classical and variant patient groups).
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the HRs were 7.8 (95%CI 1.7–36.2) for all IgG2 deficient patients and 4.0
(95%CI 0.9–18.7) for classical AT patients only (Figure 4), while the HRs
adjusted for gender varied between 8.1 and 11.5, respectively. Among
the 29 classical AT patients with IgG2 deficiency, malignancies occurred
in 45% compared to 24% among patients with normal IgG2 levels (OR
2.6, 95%CI 0.7–10.1) and 18 patients were deceased at the end of
follow-up: 10 (56%) died frommalignancies, seven (39%) from respira-
tory failure, and one (6%) patient from either a combination or both.
3.4.2. IgA deficiency
None of the patients with variant AT had an IgA deficiency. The HR
for classical AT patients with IgA deficiency was 2.2 (95%CI 0.9–5.1),
compared to classical patients with normal IgA levels. When patients
with the AT-HIGM phenotype were excluded from the analysis, the
HRwas 1.4 (95%CI 0.6–3.8), indicating that survival was similar for clas-
sical AT patients with and without IgA deficiency (Supplement 6).
Malignancies did not occur more frequently among IgA deficient pa-
tients compared to patients with normal IgA levels either (36% and
43%, respectively, OR 0.8, 95%CI 0.2–2.3). Both malignancies and respi-
ratory failurewere equally often the cause of death among IgA deficient
patients. Patient 17b was excluded from the IgA immunoglobulin anal-
ysis since IgA levels were variable during life.
3.4.3. Hyper IgM phenotype
The survival of AT patients with AT-HIGM (group 1a) was much
worse than that of classical AT patients without ATM protein but with
normal IgG levels (group 1b)(HR 8.0, 95%CI 1.6–40.1) (Figure 5) or
other AT patients with normal IgG levels (Supplement 3). All patients
with AT-HIGM died before the age of 15, three from a malignancy
(two of which were lymphomas), and four from respiratory failure. In
group 1b, five patients died from a malignancy (50%) and one from an
unknown cause (Table 1).
In addition to the seven patients in our cohort, 15 other patientswith
AT-HIGM were described in the literature [20,24–33]. We received ad-
ditional information on survival for five patients that were alive at the
time of publication (patients L2a, L3, L6, L7, and L14, Table 2). Eight of
these 15 patients were reported to have died: seven between 2 and
12 years of age and one at age 24. The remaining patients (n = 7)
were alive at the time of publication, but at least three of them died
after publication, at 10, 11, and 15 years of age.
4. Discussion
This cohort study confirmed that classical AT patients have reduced
survival compared to variant AT patients, although several classical AT
patients survived beyond 30 years of age. The presence of a malignancy
shortens the life expectancy of classical AT patients. Patients with AT-
HIGM phenotype and patients with IgG2 deficiency had reduced surviv-
al compared to classical AT patients with normal IgG and IgG2 levels, re-
spectively. The presence of ATM protein and IgA deficiency did not
influence survival in classical AT patients in the present cohort.
4.1. Variant AT and malignancies
Some have suggested that the survival time of AT patients has not
changed in the last 50 years [11]. However, classical AT patients surviv-
ing N30 years were rarely described in the past, whereas six patients in
the present study reached this age. It is well-known that patients with
Fig. 4. Survival of classical AT patients (AT-HIGM excluded) with IgG2 deficiency and patients with normal IgG2 levels.
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classical AT have a shorter life expectancy of approximately 20 years
[13,34], mainly due to earlier onset of malignancies [35,36], compared
to variant AT patients. The results from the present study are in accor-
dance with this literature, with a difference of 27 years in median age
at diagnosis of malignancies. Classical AT patients without malignancies
had a 2.5 times higher overall chance of survival compared to classical
patientswith amalignancy and theirmain cause of deathwas respirato-
ry insufficiency,which is also in linewith the available literature [11,34].
We believe that respiratory diseasesmay contribute to severe complica-
tions of cancer treatment and a short survival time after cancer diagno-
sis in AT patients with malignancies.
The 81% mortality rate due to malignancies among classical AT pa-
tients and the death of four out of five variant AT patients with a malig-
nancy are in accordance with the data of Micol et al., who described a
mortality rate of 90% for hematological malignancies and 83.3% for car-
cinomas [11]. The median time of survival after diagnosis was less than
one year for classical patients in both our and their cohort [11]. In our
variant AT patients, the youngest age at diagnosis of cancer was
23 years. This late occurrence of malignancies is probably due to the re-
sidual kinase activity and normal immunoglobulin levels protecting
these patients from the development of lymphoid malignancies, espe-
cially in childhood [35,36]. All patients without amalignancy in the var-
iant group were still alive at the end of follow-up. Future studies need
longer follow-up times to determine the final course of disease in vari-
ant AT patients.
4.2. Immunology
Immunodeficiency in general has been associated with an increased
risk of cancer [35]. This study shows that malignancies were not more
frequent in AT patientswith IgA deficiency compared to thosewith nor-
mal IgA levels. In contrast, malignancies were more common and the
major cause of death in IgG2 deficient patients compared to patients
with normal IgG2 levels. Respiratory failure was not the major cause of
death in this group, although low IgG2 levels have been associated
with a decreasedpolysaccharide antibody response, possibly causing in-
creased susceptibility to respiratory tract infections [37]. This may be
explained by the successful administration of antibiotic prophylaxis
and immunoglobulin replacement therapy to these patients.
The majority of classical AT patients had reduced levels of IgA but
none of the variant AT patients were IgA deficient, which corresponds
with the results of Staples et al. [9]. Based on similar percentages of pa-
tients with IgG2 or IgA deficiency in group 1b compared to group 2 and
the variability in immunoglobulin levels between siblings (for example
IgG2 levels in families 9 and 24 and 45 and IgA levels in families 18, 20
and 24), it seems that the immune defects in AT do not correlate with
detectability of the ATM protein.
The AT-HIGM phenotype is caused by class-switch recombination
deficiency and is characterized by decreased levels of serum IgG (and
IgG subclasses) and IgA, with normal or increased levels of serum IgM
[38]. Since recurrent sinopulmonary infections in patients with AT-
HIGMmanifest at a very young age, often before ataxia and telangiecta-
sia are present or recognized, patients with HIGM are at risk of being
misdiagnosed with ‘HIGM of undetermined cause’ instead of AT-HIGM
[8,20,24–26].
The present study, as well as all available data from the literature,
clearly revealed that HIGM strongly reduces the life expectancy in AT
patients, with respiratory failure being a common cause of death. All
seven patients in our cohort, and at least 10 out of 15 patients that
were described earlier, died before the age of 15. Of all 22 patients
with AT and HIGM described so far, no N5 (23%) survived beyond ado-
lescence. Despite intravenous immunoglobulin substitution therapy,
the AT-HIGM patients in the present cohort developed respiratory in-
sufficiency before the age of 15. This is a major point of interest since
lung function is normal in most adolescents with AT [39].
As immunoglobulin levels can vary during life, it may be difficult –
especially retrospectively - to determine if a patient truly has or had
HIGM. Patient 11 in our cohort was diagnosed with AT-HIGM at the
age of 19 and survived with his immune deficiency until death at age
40. He had a low-normal IgG level at age 10 and he did not have
Fig. 5. Survival of classical AT patients with AT-HIGM phenotype (group 1a) and patients with normal IgG levels (group 1b).
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Table 2
Review of 22 patients with AT-HIGM in the present cohort and in the literature (L).
No M/F Age Age
at
death
Cause of death Phenotype (age) Diagnosis,
chronological (age)
Serum
AFP
Mutations Siblings
with AT
Reference
1a M 13 Lymphoma Ataxia (1), telangiectasia (4),
recurrent infections
AT (2,5) ↑ See Table 2 No –
2a F 9 Respiratory failure Ataxia (1), recurrent infections
(1), telangiectasia (5)
HIGM (1), AT (1) ↑ See Table 2 Patient
2b and
2c
[8,20]
(5–3)
2b F 12 Respiratory failure Ataxia (1.5), recurrent
infections (1.5), telangiectasia
(6)
HIGM (1), AT (1) ↑ See Table 2 Patient
2a and
2c
[8,20]
(5–2)
2c M 10 Hepato-cellular carcinoma Ataxia (3), telangiectasia (9),
recurrent infections
HIGM (9), AT (9) ↑ See Table 2 Patient
2a and
2b
[20]
(5–1)
3 F 14 Respiratory failure Ataxia (1), recurrent infections
(2), telangiectasia (4)
HIGM (2), AT (2) ↑ See Table 2 No [20] (2)
4 F 9 Lymphoma Recurrent infections,
auto-immune heamolytic
anemia, neutropenia,
hepatosplenomegaly,
lympadenopathy (1), unsteady
gait (2), telangiectasia (4)
Not X-linked HIGM
(1), AT (2)
↑ See Table 2 No [20] (3),
[22]
5 F 12 Respiratory failure Recurrent infections (0.5),
ataxia (1.5)
HIGM (1), AT (2) ↑ See Table 2 No [8,20] (4)
L1b F 8 Abnormal gait,
lymphadenopathy,
hepatosplenomegaly,
telangiectasia (2–4),
lymphocytic interstitial
pneumonitis (5.5)
HIGM (4.5), AT (5) ↑ 8822insAACT
(codon 2941)
8672 del CT (codon
2945)
Not
noted
[33]
L2a F 11c Severe pneumonia Some gait disturbance (5),
chronic lung disease
Autosomal recessive
HIGM (3), AT (5)
↑ Not noted Twin
sister
with
HIGM
(L2b)
[27]
L2b F 5 Hodgkin lymphoma No neurological nor cutaneous
features
Autosomal recessive
HIGM (3), AT (5)
↑ Not noted Twin
sister
with
HIGM
(L2a)
L3 F 16c Mild ocular telangiectasia (6) Autosomal recessive
form of HIGM (6), AT
(7)
↑ Exon 48 c.6679
C N T, Exon 34
c.8484delA
Older
brother
(alive)
no
HIGM
[25]
L4 M 10 Pneumonia Not noted AT (1) Not
tested
Unknown Younger
brother
(15,
died) no
HIGM
[30]
L5 F 24 Severe pneumonia Not noted HIGM (4), AT (4) ↑ Unknown Younger
sister
(23,
alive)
no
HIGM
L6 F 10c Malignant lymphoma Recurrent infections (1),
cerebellar ataxia (2)
HIGM (1), AT (2) ↑ exon 9
c.842delAATT,
homozygous
Older
sister
(5,
died) no
HIGM
L7 M 15c Multi-organ failure due to bladder
hemorrhage
Recurrent infections (2),
cerebellar ataxia (5)
HIGM (2), AT (5) ↑ exon 10
c.902_1065del164,
exon 21
c.2877C N G
Younger
brother
(9,
alive)
no
HIGM
L8 F 7 Bleeding as side effect of
radiotherapy for Wilms tumor
Recurrent infections (2.5),
ataxia (4), no telangiectasia
Autosomal recessive
form of HIGM (2.5),
AT (5)
↑ Exon 28 3848T N C,
Exon 62
8766_8767insT
Not
noted
[32]
L9 M 11 Severe pneumonia, AML Recurrent infections (2), ataxia
and ocular telangiectasia (5)
HIGM (2), AT (5) ↑ Exon 15 C 2413➔T,
Exon 9 del1402–3,
AA
Not
noted
[28,29]
(K)
L10 F 8 Respiratory failure due to
pneumonia
Gait disturbance and ocular
telangiectasia (4)
HIGM (2), AT (4) ↑ Exon 53
c.8250C N T,
Not
noted
[24]
(continued on next page)
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recurrent infections during childhood (in contrast to all patients in
group 1a). During adulthood, his IgG levels spontaneously increased to
normal, although the IgG only consisted of IgG1. Therefore, we assume
that he did not have HIGM during childhood and excluded him from
group 1a (‘AT-HIGM’). The same holds true for patients 15b and 18a,
who developed hypogammaglobulinemia in puberty. In addition, it
may be questioned whether the two patients with AT and HIGM who
survived beyond15 years of age (patients L3 and L5, see Table 2), indeed
hadAT-HIGM. Patient L3, described by Soresina et al. [25] had an IgG de-
ficiency with high IgM and normal IgA levels while suffering from pro-
teinuria in early childhood, but normal IgA and IgG levels during
immunoglobulin substitution therapy in November 2015. So her
hypogammaglobulinemia may have been secondary to proteinuria. Pa-
tient L5’s immunoglobulin levels at the time of diagnosis were unavail-
able. Similar to the hypothesis regarding our patient 11 (see above), she
may have developed AT-HIGM later in life.
In our cohort, patients with the same ATMmutations expressed dif-
ferent phenotypes for AT-HIGM, even some that were siblings. This has
also been described previously [25,27,30] (Table 2) and confirms that
no correlation exists between ATM mutations and AT-HIGM
phenotypes.
As AT is a severe disease, affecting - among others – the nervous sys-
tem and the immune system, high-risk therapies targeting the underly-
ing molecular aspects may be considered. This is illustrated by former
administration of stem cell transplantation to patients with AT [31,40,
41] and in patients with other neurodegenerative diseases [42] and pri-
mary immunodeficiencies [43]. Due to the poor prognosis of AT patients
with HIGM, we believe that these patients are among the first eligible
candidates to study the efficacy and safety of such therapies, as this
group is expected to profit most from this therapy. Needless to say, no
other accountable cause for the IgG deficiency should exist, and HIGM
should be present since early childhood and not be a paraneoplastic fea-
ture. Since neonatal screening for severe primary immunodeficiency
diseases is upcoming in some countries, patients may be diagnosed
with AT before the first clinical symptoms emerge [44,45]. The presence
of HIGM in some of these young pre-symptomatic children can be used
as a prognostic marker for a poor outcome.
4.3. Strengths and limitations
The strengths of this study are the large number of well-
characterized AT patients, the inclusion of patients from different eth-
nicities, and the extensiveness of the data set. All but the Icelandic
patients lived in the Netherlands and benefited from the National
Health Care system.
The present cohort contained many young children, but sensitivity
analyses excluding patients with b10 years of follow-up did not lead
to essential changes in results. As groups 1a and 4 included mainly fe-
male patients, adjustments for gender did affect some estimates, but
not the interpretation of the results. While studying the Kaplan-Meier
curves, for instance in Fig. 2, one may erroneously assume that over
50% of variant AT patients survived beyond 50 years of age, and that
25% of classical AT patients survived beyond 40 years of age. As listed
in Table 1 and in the table underneath Fig. 2, however, only 5 out of
13 variant AT patients (38%) and 3 out of 48 classical AT patients (6%)
survived beyond 50 and 40 years, respectively. The other 5 variant AT
patients and 20 classical AT patients were still alive, but much younger
at the time of study and were therefore censored in the analysis. These
large numbers of patients with relatively short follow-up times may
lead to unrealistically positive cumulative probabilities of survival
shown in the Kaplan-Meier curves.
Given the rarity of AT, this study includes a relatively large number
of patients. Nevertheless, the main limitations of the study are due to
small sample sizes, especially in subgroup analyses. As a result, the
data must be interpreted with caution and further investigations with
larger cohorts of AT patients are needed to confirm our results. Fortu-
nately, an international effort to register as many patients as possible
is now ongoing. Exclusion of patients that were lost to follow-up, miss-
ing patients with a mild phenotype that were not diagnosed, publica-
tion bias, and unavailability of immunoglobulin levels may have
caused selection and/or information bias, but the number of patients
with missing data was small. Although this study spanned several de-
cades and management of AT patients might have changed over the
years, survival was not influenced by cohort effects of year of birth or
diagnosis.
5. Conclusion
AT is known as a disease with a highly reduced life expectancy, but
we described several patients with classical AT who survived longer
than would be expected. On the other hand, this study is the first to
show that IgG2 deficiency and HIGM negatively influence survival in
AT patients, and to give an overview of all patients with AT and HIGM
described in the literature. We believe that AT patients with HIGM are
at extremely high risk of early death, and are therefore most eligible
for future therapeutic trials.
Table 2 (continued)
No M/F Age Age
at
death
Cause of death Phenotype (age) Diagnosis,
chronological (age)
Serum
AFP
Mutations Siblings
with AT
Reference
(p.2622Ala N Val)
homozygous
L11 M 8 Recurrent infections (0.5),
ataxia (3), telangiectasia (6)
HIGM (3), AT (6) Unknown Exon 54
c.7788G N A, IV564–
2189 del 16.kb
(intron 63)
Not
noted
[20]
L12 F 12 Respiratory failure Recurrent infections (1), ataxia
(9), telangiectasia (9)
HIGM (1), AT (9) Unknown Unknown Not
noted
L13 M 2 Post-transplant-lymhoproliferative
disorder
No clinical features of AT HIGM phenotype
disorder (primary
immunodeficiency
with unknown
cause)(2), AT (post
mortem)
↑ Exon 12
c.1316T N C/439LNP,
homozygous
Not
noted
[31]
L14 F 8c Ocular telangiectasia, motor
and intellectual impairment (3)
HIGM (2), AT (3) ↑ Exon 44,
c.6198 + 1G N T,
homozygous
Healthy
brother
[26]
a Patients 1–5: Patients from the present cohort, numbers are in accordance with Table 1.
b Patients L1-L14: Patients from the literature search.
c Age at 1–11-2015, or age of death (not reported in the literature).
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